Strides Pharma jumps on positive outcome of COVID-19 vaccine trials

Strides Pharma Science rallied 7.70% to Rs 336.50 after the company’s subsidiary Biolexis and Akston Biosciences announce encouraging top-line results from phase II/III trial of their thermostable 2nd gen COVID-19 vaccine. The vaccine was well tolerated, with no reported safety issues and is shelf-stable for over six months at room temperature at 25 celsius and potency for one month at 37 celsius. The interim analysis showed 91% seroconversion rate at day 56. The vaccine will be produced at Stelis Biopharma, the biotech contract development and manufacturing company (CDMO) of Strides group. Akston and Strides group have already signed a licensing, manufacturing, and commercialization agreement to launch this vaccine worldwide as AmbiVax-C. Read more >>